Enliven Therapeutics ELVN Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's change in lease liabilities?
- Enliven Therapeutics (ELVN) reported change in lease liabilities of -$97K in Q1 2026.
- How has Enliven Therapeutics's change in lease liabilities changed year-over-year?
- Enliven Therapeutics's change in lease liabilities decreased by 40.6% year-over-year, from -$69K to -$97K.
- What is the long-term trend for Enliven Therapeutics's change in lease liabilities?
- Over 2 years (2023 to 2025), Enliven Therapeutics's change in lease liabilities has grown at a 4.3% compound annual growth rate (CAGR), from -$310K to -$337K.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.